Carmot Therapeutics Inc. (CRMO)
Carmot Therapeutics was planning to go public, but the IPO was withdrawn on Dec 11, 2023.
Stock Price: Pending
IPO price not available yet
Carmot Therapeutics Statistics
Total Valuation
Market Cap | n/a |
Enterprise Value | n/a |
Important Dates
Earnings Date | n/a |
Ex-Dividend Date | n/a |
Share Statistics
Current Share Class | n/a |
Shares Outstanding | n/a |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | n/a |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | n/a |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
Current Ratio | n/a |
Quick Ratio | 11.87 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -7.97 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | n/a |
Return on Capital (ROIC) | n/a |
Revenue Per Employee | n/a |
Profits Per Employee | -$876,034 |
Employee Count | 59 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | -444,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
Beta (5Y) | n/a |
52-Week Price Change | n/a |
50-Day Moving Average | n/a |
200-Day Moving Average | n/a |
Relative Strength Index (RSI) | n/a |
Average Volume (20 Days) | n/a |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -67.18M |
Pretax Income | -52.13M |
Net Income | -51.69M |
EBITDA | -45.67M |
EBIT | -46.32M |
Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has $138.34 million in cash and $4.06 million in debt, giving a net cash position of $134.29 million.
Cash & Cash Equivalents | 138.34M |
Total Debt | 4.06M |
Net Cash | 134.29M |
Net Cash Per Share | n/a |
Equity (Book Value) | -63.71M |
Book Value Per Share | n/a |
Working Capital | 131.29M |
Cash Flow
In the last 12 months, operating cash flow was -$55.73 million and capital expenditures -$1.74 million, giving a free cash flow of -$57.47 million.
Operating Cash Flow | -55.73M |
Capital Expenditures | -1.74M |
Free Cash Flow | -57.47M |
FCF Per Share | n/a |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
CRMO does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | n/a |
Shareholder Yield | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | n/a |